Goldman Sachs analyst Asad Haider assumed coverage of AbbVie (ABBV) with a Neutral rating and $194 price target The company’s “strong” growth for “commercial powerhouses” Skyrizi and Rinvoq has now become more fully appreciated with mid-term consensus forecasts sitting above management’s guidance for the first time since these drugs launched, the analyst tells investors in a research note. The firm says this puts the onus for positive surprises to emerge out of other parts of AbbVie’s portfolio where it sees tougher near-term setup.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Salesforce, Block, AbbVie, Applied Materials, Oracle: Insider Moves Unveiled!
- China announces retaliatory tariffs, U.S. unemployment rises: Morning Buzz
- Closing Bell Movers: Futures continues to slip ahead of key jobs data
- AbbVie sees Q1 adjusted EPS with expenses $2.34-$2.38, consensus $2.51
- AbbVie sees FY25 adjusted EPS with expenses $11.99-$12.19, consensus $12.28